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1 Introduction
The observation by LlGGINS and HOWIE [12]
that antenatal administration of corticoids reduces
the risk of respiratory distress syndrome (RDS) in
newborns had been confirmed by several investi-
gators, resulting in an increased use of this prophy-
lactic treatment.
Treatment with corticoids accelerate the synthesis
of the surface-active dipalmitoyl lecithin in the
lungs by stimulating the cholin phosphotrans-
ferase activity [7]. In animal studies, however,
corticoid administered antenatally has been found
to cause several side effects by partly unclarified
mechanisms demonstrated by a reduced weight
of thymus, suprarenal glands, liver, pancreas,
lungs, heart and placenta [2, 9, 10].
In humans no permanent side effects after
antenatal corticoid treatment had been
demonstrated. Similarly it is uncertain whether
acute side effects occurs. It is still under discus-
sion whether the risk of infection in mothers and
infants is increased after treatment with corticoids
in pregnancies complicated by prolonged rupture
of the membranes [6, 11]. Already LlGGINS and
HOWIE (1972) [12] suggested that there may be
an increased risk of fetal death in pregnancies
complicated by preeclampsia and treated with
corticoid, but this likewise wait for a clarification.
Maternal blood pressure in hypertensive women is
not affected by corticoid therapy [15]. However,
development of pulmonary edema in women after
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treatment with betamimetics and corticoids is
described in a few cases [13, 14].
Administration of corticoids in high doses to new-
born mice and rats reduces the DNA-incorporation
in the brain [4, 8]. Betamethasone given in high
doses every other day for a total of three doses to
pregnant rhesus monkeys likewise causes a reduc-
tion of both size and DNA-concentration of the
brains in the offspring [5]. Betamethasone given to
rhesus monkeys for 13 days prior to delivery in
doses equivalent to those given to humans results
in reduced head circumference of their offspring
compared to saline-treated control animals. How-
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ever, no reduction of the head circumference was
seen after treatment with betamethasone in same
doses for only 3 days [10].
Therefore, it was found important to realize if
reduction of brain size was found after corticoid
treatment in humans. This paper reports on
occipitofrontal circumference in newborns of
betamethasone-treated women as compared with
the circumference at .time of birth according to
reference curves.
2 Material and methods
The material is comprised of two groups treated
with different corticoids. The first group com-
prises 46 newborns whose mothers during the
period January 1977-March 1978 were treated
antenatally with Celeston® (3 mg betamethasone-
acetate + 3 mg betamethasone-disodiumphosphate
per ml)*. A dose of two ml was given daily intra-
muscularly for three consecutive days. The gesta-
tional age at birth was 34—41 weeks. The second
group comprises 52 infants of mothers treated
with Celestona® (4 mg betamethasone-disodium-
phosphate per ml)*. Two ml were given intra-
muscularly daily for three consecutive days. The
gestational age at birth was 35—40 weeks. This
part of the study took place in the period
March 1978-March 1979.
The indication for corticoid treatment was immi-
nent preterm delivery. Twins, cases of uncertain
gestational age and cases of intrauterine death
were excluded before the calculations. There were
no cases of diabetes mellitus in the two groups
treated with corticoids.
Gestational age was estimated from the first day of
the last menstrual period.
The occipitofrontal circumference was rounded
off to half or whole centimers. Same type of fiber-
glas tape was used in all the measurements. It is a
common experience that varying length of the
occipitofrontal circumference are obtained due to
different measuring technique. Three sets of
measurements done blindly in five different
infants gave a maximal variation of 0.3 cm for
each infant.
The control group consisted of 1012 infants born
at Herlev Hospital in 1978. Excluded were non-
caucasian infants, twins, stillborns, cases of uncer-
tain gestational age and infants of mothers treated
with corticoid. For each gestational week a curve
was traced, for boys as well as for girls, using the
occipitofrontal circumference in centimeters as
abscissa and the number of children as ordinate.
Curves were traced both in cases including
placental insufficiency and without.
Placental insufficiency was defined as low or
decreasing estriol and/or human placental lactogen.
These parameters were measured routinely in all
patients from the 30th week. Thus, the cases with
placental insufficiency include severe cases (small
for gestational age) and light cases (appropriate for
gestational age).
3 Results
Tab. I shows the number of normal infants in
different gestational age, as well as average
occipitofrontal circumference.
Tab. I. Occipitofrontal circumference in non-treated new-


























































Celeston® and Celestona® (Schering Corp.).
Fig. 1 shows the reference curve for the occipito-
frontal circumference at the time of delivery in
different gestational ages for boys and girls. The
90, 50 and 10 percentiles are indicated. The curve
for girls is found to be approximately one half
centimeter below that of the boys. The weekly
increase is above one half centimeter. The average
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Tab. II. Occipitofrontal circumference at time of birth in
infants treated with Celeston® compared with the circum-
ference in non-treated infants. Cases with placental insuf-
ficiency excluded. Celeston® administered more than
















































Occipitofrontal circumference for infants treated
with Celeston® and Celestona® are shown in
Fig. 2A—B. The average Occipitofrontal circum-
ference were found to be normal except in the















Fig. 2 A. Occipitofrontal circumference at birth in all boys
of mothers treated with celeston and celestona compared
















Fig. 2 B. Occipitofrontal circumference at birth in all girls
of mothers treated with celeston and celestona compared
to normal Occipitofrontal circumference outlined as
percentiles.
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Fig. 3 A. Occipitofrontal circumference in boys of
mothers treated with celeston and celestona. Cases with
placental insufficiency are excluded. Corticoid adminis-











Fig. 3 B. Occipitofrontal circumference in girls of mother^
treated with celeston and celestona. Cases with placental
insufficiency are excluded. Corticoid administratered
more than 7 days before birth.
Tab. III. Occipitofrontal circumference at time of birth in
infants treated with Celestona® compared with the
circumference in non-treated infants. Cases with placental
insufficiency excluded. Celestona® administered more






































































on cases in which corticoids were given more than
7 days before delivery and in which no placental
dysfunction was diagnosed, no deviation from
the normal were found (Tab. II and III, and
Fig.3A-B).
4 Comment
As mentioned, corticoids exert an impeding effect
on the evolution of the brain. This effect is seen
after large doses of corticoids or long-term treat-
ment. In their experiments with rhesus monkeys
JOHNSON et al. [10] were not able to show a sig-
nificant reduction of the Occipitofrontal circum-
ference at birth after short term betamethasone
treatment with doses equivalent to .those used in
human treatment. Likewise no reduction of the
Occipitofrontal circumference at birth was found
in the present investigation when cases with
placental dysfunction are excluded.
However, it is still possible that Celeston® may
have an impeding effect on brain growth in boys.
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Verder et al. Occipitofrontal circumference 269
But the group treated with Celeston® contains
only two boys without placental dysfunction.
In the present study no correction was done in the
last trimester on the gestational age on the basis of
biparietal diameter or estimated fetal weight. So,
small or large fetal measurements could be due to
inhibition or acceleration of the fetal growth. The
estimation of the gestational age has a range of
± 2—3 weeks due to the biological variation in the
time-span between the first day of the menstrual
period and the ovulation and between the ovula-
tion and birth [3]. Measurement of biparietal
diameter in early pregnancy opens up the possibil-
ity of a more precise dating of the gestational age
in pregnancies with uncertain last menstrual
period. However, babies with uncertain gestational
age was excluded in the present investigation.
LIGGINS and HOWIE [12] found no intellectual
reduction in 4-year-old children whose mothers
were treated with betamethasone in pregnancy.
However, these findings do not disprove a retarda-
tion in the examined childrens brain evolution.
The corticoid effect on the brain is complex and
different brain parts are affected in different ways
[4]. It is probable that corticoids in some cases can
delay development of the brain without causing
permanent damage on the nerve cells. DE LEMOS
et al. [5] found a significant reduction of the brain
weight, head circumference and the DNA-content
in the brain of rhesus fetuses after administration
of large doses of dexamethasone every other day
for a total of three doses. Six months after
delivery the difference in DNA-content of the
brain, brain weight and head circumference had
narrowed between the control group and the
group which had received steroid. In agreement
with this, COTTERRELL et al. [4] found an inhibi-
tion of thymidin incorporation in cerebral cells of
rats after treatment with cortisol during the first
4 days after birth. At the age of 13—20 days an
accelerated mitotic activity in the brain was found
in the treated rats. BARRADA et al. [2] like other
investigators found a reduction in the weight of
the fetal rabbit brain after treatment with beta-
methasone. The DNA-concentration in the brain
and total number of brain cells, however, was not
affected and the concentrations of brain phos-
pholipids and protein were higher in the treated
fetuses.
BALLARD etal. [1] have shown that beta-
methasone used in humans results in a corticoid
concentration in the cord blood, corresponding to
that seen in untreated preterm infants developing
RDS. Thus, the effect of corticoid administered
antenatally is comparable to a physiological stress
in the fetus. Possible for this reason antenatal
corticoid treatment in humans in usual doses is
not so dangerous as compared with high dose
treatment in animal studies. The data found in the
actual study are in agreement with this theory.
Summary
Celestona® (betamethasone-disodiumphosphate) and
Celeston® (betamethasone-acetat + betamethasone-dis-
odiumphosphate) given intramuscularly to pregnant
women in order to reduce the frequency of respiratory
distress syndrome does not reduce the occipitofrontal
circumference of the newborn infants. Before the results
from the actual work were available an impeding effect of
the evolution of the brain was found in the light of animal
experiments.
The material is comprised of 52 newborn infants whose
mothers were treated with Celestona® 8 mg daily for 3
days and 46 infants treated with Celeston® 12 mg daily
for 3 days. The untreated population comprises 1012
newborn infants.
Excluded were non-caucasian infants, twins, stillborns
and cases of uncertain gestational age. The occipitofrontal
circumference in normal infants and those infants treated
with betamethasone were compared in Figs. 2 and 3.
Focusing only upon cases in which corticoids were given
more than 7 days before delivery and in which no
placental dysfunction was diagnosed, no differences from
the normal were found (Tabs. II and III, and Figs. 3 A
and B).
Keywords: Betamethasone, brain growth-intrautcrine, glucocorticoids-antenatal prophylaxis, newborns, occipito-
frontal circumference.
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Zusammenfassung
Occipitofrontaler Umfang bei Neugeborenen von mit
Betamethason behandelten Müttern
Zur Vermeidung eines RDS wurde schwangeren
Frauen Celestona® (Betamethasondinatriumphosphat)
bz\v. Celeston® (Betamethasonacetat + Betamethasondi-
natriumphosphat) intramuskulär verabreicht. Danach fand
sich bei den Neugeborenen keine Reduzierung des occipitp-
frontalen Unifangs. Bevor die Ergebnisse dieser Arbeit
vorlagen, wurde aus Tierexperimenten abgeleitet, daß ein
Effekt auf die Gehirnentwicklung möglich ist.
Unser Untersuchungskollektiv bestand aus 52 Neugebore-
nen, deren Mütter 3 Tage lang mit 8 mg Celestona® pro
Tag und 46 Kindern, deren Mütter 3 Tage lang mit 12 mg
Celeston pro Tag behandelt worden waren. Die Kontroll-
gruppe umfaßte 1012 Neugeborene. Unberücksichtigt
blieben nichtkaukasische Kinder, Zwillinge, Totgeborene
und Kinder mit unsicherem Gestationsalter. Die occipito-
frontalen Umfange der Untersuchungs- und der Kontroll-
gruppe werden in Figs. 2 und 3 einander gegenübergestellt.
Betrachtet man nur Fälle, in denen die Kortikoidgabe
mehr als 7 Tage vor der Geburt erfolgte und in denen
keine Plazentainsuffizienz vorlag, so ergaben sich keine
Abweichungen gegenüber der Kontrollgruppe (Tabs. II
und III, Figs. 3 A und B).
Schlüsselwörter: Antenatale Glukokortikoidprophylaxe, Betamethason, intrauterines Gehirnwachstum, Neugeborene,
occipitofrontaler Umfang.
Resume
Circonference occipito-frontale des nouveaux-nes de
meres traitees par betamethasone
Le Celestona® (betamethasone-disodium phosphate) et le
Celeston® (acetate de betamethasone + bethamethasone-
disodiumphosphate) donnes en intra-musculaire aux
femmes enceintes afin de diminuer la frequence du
syndrome de detresse respiratoire, ne diminuent pas la
circonference occipito-frontale des nouveaux-nos. Avant
les resultats des travaux actuels, on avait trouve aux vues
des experimentations animales une entrave au
developpement cerebral.
Le materiel consiste en 52 nouveaux-nes dont les meres
avaient ete traitees avec du Celestona® ä la dose de 8 mg
par jour pendant 3 jours et en 46 enfants dont les meres
avaient ete trait 6es avec du Celeston® ä la dose de 12 mg
par jour pendant 3 jours. La population non traitee
comporte 1012 nouveaux-nes.
Les enfants non caucasiens, les jumeaux, les morts-nes et
les cas avec un terme gestationel incertain ont ete exclus.
Les circonfererices occipito-frontales des enfants normaux
et des enfants traites par betam6thasone sont comparees
dans les Figs. 2 et 3. Si ne s'occupe que des cas ayant
regu des cortico'ides plus de 7 jours avant 1'accouchement
et chez lesquels on n'a pas diagnostique d'insuffisance
placentaire, on ne trouve pas de difference par rapport
aux temoins (Tabs. II et III, et Figs. 3 A et B).
Mots-cles: Betamethasone, circonference occipito-frontale, croissance cerebrate intra-uterine, nouveaux-nes,
prophylaxie par glucocortico'ides antenataux.
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